DCF Advisers LLC Purchases Shares of 30,500 Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• DCF Advisers acquired 30,500 Zimmer Biomet shares during the second quarter, valued at approximately $2.63 million. Institutional investors and hedge funds collectively own 88.89% of the company.
• Zimmer Biomet reported quarterly earnings of $2.07 per share and revenue of $2.18 billion, exceeding analyst estimates; revenue increased 4.8% year over year.
• ZBH was trading at $100.65, while analysts maintained a consensus “Hold” rating with an average price target of $104.42. The company also pays a quarterly dividend of $0.24 per share, yielding about 1.0% annually.

DCF Advisers LLC acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 30,500 shares of the medical equipment provider's stock, valued at approximately $2,626,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ZBH. DV Equities LLC acquired a new position in Zimmer Biomet in the fourth quarter worth approximately $25,000. Tacita Capital Inc acquired a new stake in shares of Zimmer Biomet during the 2nd quarter valued at $26,000. Monetary Solutions Ltd acquired a new stake in shares of Zimmer Biomet during the 4th quarter valued at $30,000. Gen Wealth Partners Inc bought a new stake in shares of Zimmer Biomet during the 4th quarter worth $31,000. Finally, Elevation Wealth Partners LLC boosted its stake in shares of Zimmer Biomet by 145.9% during the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider's stock worth $33,000 after acquiring an additional 229 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Up 1.5%

NYSE:ZBH opened at $100.65 on Thursday. The business's fifty day moving average price is $92.16 and its 200 day moving average price is $90.85. The firm has a market capitalization of $19.20 billion, a price-to-earnings ratio of 24.49, a PEG ratio of 2.70 and a beta of 0.45. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $108.29.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts' consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The firm had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same period last year, the company posted $2.07 EPS. The business's quarterly revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.53 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, July 31st. Investors of record on Thursday, June 25th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date was Thursday, June 25th. Zimmer Biomet's dividend payout ratio (DPR) is currently 23.36%.

Insider Buying and Selling

In related news, insider Sang Yi sold 5,000 shares of the business's stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider directly owned 27,251 shares of the company's stock, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.28% of the company's stock.

Analyst Ratings Changes

ZBH has been the topic of a number of recent analyst reports. Truist Financial boosted their target price on Zimmer Biomet from $92.00 to $106.00 and gave the stock a "hold" rating in a research report on Thursday, August 6th. Citigroup dropped their price target on Zimmer Biomet from $95.00 to $93.00 and set a "neutral" rating on the stock in a research note on Thursday, May 28th. JPMorgan Chase & Co. cut their price objective on Zimmer Biomet from $100.00 to $95.00 and set a "neutral" rating on the stock in a report on Wednesday, April 29th. UBS Group reaffirmed a "buy" rating and set a $120.00 price objective on shares of Zimmer Biomet in a research note on Thursday, August 6th. Finally, Canaccord Genuity Group raised their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a "hold" rating in a report on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $104.42.

Zimmer Biomet Company Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source